UCB

Stock performance

History

UCB was founded in 1928 by Belgian industrialist Emmanuel Janssen as Union Chimique Belge, a diversified chemicals company. Over the following decades it built pharmaceutical, chemical, and film businesses, then spent the 2000s turning itself into a pure biopharmaceutical company, buying Britain's Celltech in 2004 and Germany's Schwarz Pharma in 2006 while selling off its chemical and films divisions.

Business model

UCB develops and sells specialty medicines in two main areas, neurology and immunology. Its long-time anchor was the epilepsy drug Keppra, and it now leans on newer products such as the psoriasis and arthritis antibody Bimzelx, the Crohn's and arthritis drug Cimzia, epilepsy treatments including Briviact and Fintepla, and the osteoporosis drug Evenity developed with Amgen. Revenue depends on bringing new drugs through late-stage trials fast enough to replace those losing patent protection.

Market position

UCB is a mid-sized biopharma company by global standards, far smaller than the likes of Roche or Novartis, but a leader in epilepsy treatment and an increasingly important player in immunology since Bimzelx's launches in Europe and the US. That product's rapid uptake turned UCB into one of Europe's better-performing pharmaceutical stocks in the mid-2020s, after a period when patent expiries had weighed on growth.

Country impact

UCB is one of Belgium's largest companies and its main homegrown pharmaceutical group, part of a broader life-sciences cluster (alongside large Pfizer, GSK, and Johnson & Johnson sites) that makes pharmaceuticals one of Belgium's biggest export categories. Its research and manufacturing base in Braine-l'Alleud supports a significant number of highly paid R&D jobs in Wallonia.